Is BNB Plus Corp. (BNBX) a Buy, Sell, or Hold?
NASDAQ : BNBX
BNB Plus Corp.
$0.163 USD
$0 (0.0%)
- Volume
- 4.59M
- Average Volume
- 887.95K
- Market Capitalization
- $210.49K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $7.15
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.82
Company Overview
NASDAQ
Clay D. Shorrock
Biotechnology
Healthcare
BNBX
26
US
USD
Liquidity Metrics
0.00
1.82
1.74
0.64
0.00
Sales & Valuation
$2.14M
0.10
0.13
-0.02
-1.42
Profitability
-$134.23
-$15.16M
-1646.94%
-1670.74%
-337.10%
-252.85%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Poll Results
About BNB Plus Corp. (NASDAQ:BNBX) Stock
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Ta ... gging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
2026-07-13 07:39:00
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company") today announced that it has received a delisting determination from the Hearing Panel of the Nasdaq Stock Market LLC ("Nasdaq") as a result of the Company's non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Delisting Determination”). In accordance with applicable Nasdaq rules, the Company in.
BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing
2026-05-26 08:00:00
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M (the "Financing"). Proceeds from the Financing will be used to bolster the Company's digital asset treasury and will provide working capital in support of a comprehensive strategic review. With the anticipated proceeds, the Company exp.
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order
2026-04-23 07:00:00
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed production of its largest order in LineaRx history. The $1.2 million order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of th.
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
2026-04-20 07:00:00
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. Strategic Review and Treasury Value The strategic alternatives under consideration include, but are not limited to, a merger, reverse merger, b.
Frequently Asked Questions
-
What is the current BNB Plus Corp. (BNBX) stock price?
-
BNB Plus Corp.(NASDAQ:BNBX) stock price is $0.163 in the last trading session. During the trading session, BNBX stock reached the peak price of $7.15 while $0.11 was the lowest point it dropped to. The percentage change in BNBX stock occurred in the recent session was 0.0% while the dollar amount for the price change in BNBX stock was $0.
-
BNBX's industry and sector of operation?
-
The NASDAQ listed BNBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BNBX?
-
Patrick Brian Horsman | Chief Investment Officer
Sanjay Hurry | Executive Director of Investor Relations & Corporate Communications
Judith Murrah | Director, Strategic Transition Advisor & Secretary
Clay Shorrock | President & Chief Executive Officer
Beth Jantzen | Chief Financial Officer -
How many employees does BNBX have?
-
Number of BNBX employees currently stands at 26. BNBX operates from 50 Health Sciences Drive, Stony Brook, NY 11790, US.
-
Link for BNBX official website?
-
Official Website of BNBX is: https://www.bnbx.io
-
How do I contact BNBX?
-
BNBX could be contacted at phone #631 240 8800 and can also be accessed through its website. BNBX operates from 50 Health Sciences Drive, Stony Brook, NY 11790, US.
-
How many shares of BNBX are traded daily?
-
The average number of BNBX shares traded daily for last 3 months was 887.95K.
-
What is the market cap of BNBX currently?
-
The market value of BNBX currently stands at $210.49K with its latest stock price at $0.163